JP2024532810A5 - - Google Patents

Info

Publication number
JP2024532810A5
JP2024532810A5 JP2024508786A JP2024508786A JP2024532810A5 JP 2024532810 A5 JP2024532810 A5 JP 2024532810A5 JP 2024508786 A JP2024508786 A JP 2024508786A JP 2024508786 A JP2024508786 A JP 2024508786A JP 2024532810 A5 JP2024532810 A5 JP 2024532810A5
Authority
JP
Japan
Prior art keywords
composition
antigen
combination
pharmaceutically acceptable
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532810A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074903 external-priority patent/WO2023019242A1/en
Publication of JP2024532810A publication Critical patent/JP2024532810A/ja
Publication of JP2024532810A5 publication Critical patent/JP2024532810A5/ja
Pending legal-status Critical Current

Links

JP2024508786A 2021-08-13 2022-08-12 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 Pending JP2024532810A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163233163P 2021-08-13 2021-08-13
US63/233,163 2021-08-13
PCT/US2022/074903 WO2023019242A1 (en) 2021-08-13 2022-08-12 Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Publications (2)

Publication Number Publication Date
JP2024532810A JP2024532810A (ja) 2024-09-10
JP2024532810A5 true JP2024532810A5 (cg-RX-API-DMAC7.html) 2025-08-19

Family

ID=83192025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508786A Pending JP2024532810A (ja) 2021-08-13 2022-08-12 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法

Country Status (7)

Country Link
US (1) US20240351977A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384495A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532810A (cg-RX-API-DMAC7.html)
KR (1) KR20240046744A (cg-RX-API-DMAC7.html)
CN (1) CN118076582A (cg-RX-API-DMAC7.html)
CA (1) CA3228238A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023019242A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12697320B2 (en) 2021-01-29 2026-08-04 Tim Therapeutics, Inc. Tartaric acid analogs and uses thereof
CN117940407A (zh) 2021-08-13 2024-04-26 Lapix生物治疗股份有限公司 降低免疫不耐受和治疗自身免疫病症的组合物和方法
US20260144239A1 (en) 2022-10-25 2026-05-28 Lapix Therapeutics, Inc. Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models
WO2024118602A1 (en) 2022-11-29 2024-06-06 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859284B2 (en) * 2009-10-22 2014-10-14 The United States Of America, As Represented By The Secretary Of The Navy Delivery of nanoparticles to neurons
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
JP6783652B2 (ja) * 2013-09-24 2020-11-11 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク 抗原特異的免疫原性を低減するための組成物及び方法
ES2952038T3 (es) * 2016-04-05 2023-10-26 Univ New York State Res Found Composiciones que contienen fosfoserina para la inducción de la tolerancia inmune
US20240173389A1 (en) * 2021-03-11 2024-05-30 Lapix Therapeutics, Inc. Compositions and Methods For Reducing Immune Intolerance

Similar Documents

Publication Publication Date Title
JP2022530018A5 (cg-RX-API-DMAC7.html)
Greco et al. Sudden sensorineural hearing loss: an autoimmune disease?
JP5555431B2 (ja) 自己免疫疾患を予防し治療するための物質
JP4782675B2 (ja) ワクチン接種用スフィンゴイドポリアルキルアミン抱合体
ES2893451T3 (es) ARN para el tratamiento de enfermedades autoinmunes
AKBAR et al. Hepatitis B virus (HBV)‐transgenic mice as an investigative tool to study immunopathology during HBV infection
CA2198479A1 (fr) Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
JP2001502299A (ja) リポソーム
JP2004331668A (ja) 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための医薬、組成物およびシステム
CN103118697A (zh) 治疗肿瘤形成的免疫原性组合物及方法
US20220273791A1 (en) Selective local inhibition of tnfr1-mediated functions at the site of antigen/allergen presentation
WO2000040273A2 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
CN118076582A (zh) 降低免疫不耐受和治疗自身免疫病症的组合物和方法
Xia et al. Lung gene therapy—How to capture illumination from the light already present in the tunnel
TW202302855A (zh) 用於治療法布瑞氏症之組成物及方法
JP2025516637A5 (cg-RX-API-DMAC7.html)
JPWO2022244815A5 (cg-RX-API-DMAC7.html)
WO2023280303A1 (zh) Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物
ES2292594T3 (es) E-selectina para tratar o prevenir accidentes cerebrovasculares.
JP2023513487A5 (cg-RX-API-DMAC7.html)
JP2025505628A5 (cg-RX-API-DMAC7.html)
JP2025506429A5 (cg-RX-API-DMAC7.html)
AU2001264813A1 (en) Methods for preventing strokes by inducing tolerance to E-selectin
JP2025516636A5 (cg-RX-API-DMAC7.html)
US20250170272A1 (en) Polyomaviral gene delivery vector particle comprising a nucleic acid sequence encoding a phosphatase activity-possessing polypeptide